CLEC-2A Inhibitors
Chemical inhibitors of CLEC-2A target the protein's signaling pathways, primarily through the inhibition of protein kinase C (PKC) and related kinases, which are essential for the protein's activation through phosphorylation processes. Chelerythrine, for example, acts to hinder PKC, thus preventing the phosphorylation events necessary for CLEC-2A's function. Similarly, Gö6976 is known for its potent inhibition of PKCα and PKCβ isoforms, leading to reduced activation of proteins downstream of CLEC-2A signaling. Bisindolylmaleimide I, with its selective PKC inhibitory profile, and Ro 31-8220, also disrupt the phosphorylation cascade crucial for CLEC-2A activation. These inhibitors collectively ensure that the phosphorylation necessary for the functional activity of CLEC-2A is impeded.
In addition to these, Staurosporine serves as a broad-spectrum kinase inhibitor that affects multiple kinases that play a role in the activation of CLEC-2A, thus impeding CLEC-2A's activation at various points within its signaling pathway. Sotrastaurin and Enzastaurin, both selective PKC inhibitors, specifically target PKC which is implicated in CLEC-2A signaling, with Enzastaurin showing a preference for PKCβ inhibition. Ruboxistaurin, another PKCβ-specific inhibitor, similarly prevents the phosphorylation required for CLEC-2A's activation. K252a, with its wider kinase target profile, also prevents kinase activity that would otherwise lead to CLEC-2A activation. The compound C1, or Calphostin C, serves as a potent inhibitors of PKC, thereby interfering with the phosphorylation cascade necessary for CLEC-2A's functional activity. Lastly, Midostaurin targets multiple kinases, thereby preventing activation of CLEC-2A by inhibiting the kinases involved in its signaling pathways. Each of these inhibitors can functionally inhibit the activity of CLEC-2A by blocking the phosphorylation steps needed for its activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Chelerythrine | 34316-15-9 | sc-507380 | 100 mg | $540.00 | ||
Chelerythrine is known to inhibit protein kinase C (PKC). Since CLEC-2A signaling is dependent on the phosphorylation events mediated by kinases, the inhibition of PKC can lead to a reduction in CLEC-2A signaling activity by preventing its necessary phosphorylation, thus functionally inhibiting CLEC-2A. | ||||||
Gö 6976 | 136194-77-9 | sc-221684 | 500 µg | $227.00 | 8 | |
Gö6976 is a potent inhibitor of PKCα and PKCβ. By inhibiting these PKC isoforms, Gö6976 can prevent the phosphorylation and activation of downstream proteins that are essential for the full activation of CLEC-2A, thereby functionally inhibiting CLEC-2A. | ||||||
Bisindolylmaleimide I (GF 109203X) | 133052-90-1 | sc-24003A sc-24003 | 1 mg 5 mg | $105.00 $242.00 | 36 | |
This compound is a selective inhibitor of PKC, which is involved in the activation of various signaling pathways including those related to CLEC-2A. By inhibiting PKC, Bisindolylmaleimide I can prevent the activation of CLEC-2A that relies on PKC-mediated signaling, thereby functionally inhibiting CLEC-2A's activity. | ||||||
Ro 31-8220 | 138489-18-6 | sc-200619 sc-200619A | 1 mg 5 mg | $92.00 $245.00 | 17 | |
Ro 31-8220 is another PKC inhibitor that can disrupt the phosphorylation events necessary for CLEC-2A signaling. Through its inhibition of PKC, Ro 31-8220 can prevent the activation of CLEC-2A, leading to functional inhibition of the protein. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that affects various kinases, including those that are upstream of CLEC-2A. By inhibiting these kinases, Staurosporine can impede the phosphorylation cascade necessary for CLEC-2A activation, leading to functional inhibition of CLEC-2A. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is a selective inhibitor of PKC, which plays a role in the signaling pathways that activate CLEC-2A. Inhibition of PKC by Sotrastaurin would lead to reduced phosphorylation and activation of CLEC-2A, thus functionally inhibiting CLEC-2A. | ||||||
Enzastaurin | 170364-57-5 | sc-364488 sc-364488A sc-364488B | 10 mg 50 mg 200 mg | $259.00 $612.00 $1721.00 | 3 | |
Enzastaurin is a selective PKCβ inhibitor. It can inhibit the kinase activity of PKCβ which is potentially involved in the activation of CLEC-2A signaling pathways. Through the inhibition of PKCβ, Enzastaurin can lead to functional inhibition of CLEC-2A by preventing its necessary phosphorylation events. | ||||||
Ruboxistaurin | 169939-94-0 | sc-507364 | 25 mg | $1080.00 | ||
Ruboxistaurin, a selective inhibitor of PKCβ, can impede the phosphorylation events required for CLEC-2A activation. With the specific inhibition of PKCβ, Ruboxistaurin can functionally inhibit CLEC-2A by preventing the phosphorylation cascade that CLEC-2A depends on for its activity. | ||||||
K-252a | 99533-80-9 | sc-200517 sc-200517B sc-200517A | 100 µg 500 µg 1 mg | $129.00 $214.00 $498.00 | 19 | |
K252a is a kinase inhibitor that affects a variety of kinases, including those involved in the signaling pathways of CLEC-2A. By inhibiting these kinases, K252a can prevent the phosphorylation and subsequent activation of CLEC-2A, leading to its functional inhibition. | ||||||
Calphostin C | 121263-19-2 | sc-3545 sc-3545A | 100 µg 1 mg | $343.00 $1642.00 | 20 | |
C1, also known as Calphostin C, is a potent inhibitor of PKC. Its inhibition of PKC can prevent the phosphorylation that is essential for CLEC-2A activation, thereby functionally inhibiting CLEC-2A. | ||||||